MX372711B - Metodos para la purificacion de arilsulfatasa a. - Google Patents
Metodos para la purificacion de arilsulfatasa a.Info
- Publication number
- MX372711B MX372711B MX2015008875A MX2015008875A MX372711B MX 372711 B MX372711 B MX 372711B MX 2015008875 A MX2015008875 A MX 2015008875A MX 2015008875 A MX2015008875 A MX 2015008875A MX 372711 B MX372711 B MX 372711B
- Authority
- MX
- Mexico
- Prior art keywords
- asa
- arylsulfatase
- present
- methods
- purification
- Prior art date
Links
- 102100022146 Arylsulfatase A Human genes 0.000 title abstract 5
- 108010036867 Cerebroside-Sulfatase Proteins 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 238000000746 purification Methods 0.000 title 1
- 239000012620 biological material Substances 0.000 abstract 1
- 239000006143 cell culture medium Substances 0.000 abstract 1
- 238000004587 chromatography analysis Methods 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
- 238000002641 enzyme replacement therapy Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000000108 ultra-filtration Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
- C12M47/12—Purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06001—Arylsulfatase (3.1.6.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Sustainable Development (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750693P | 2013-01-09 | 2013-01-09 | |
| PCT/US2014/010856 WO2014110246A1 (en) | 2013-01-09 | 2014-01-09 | Methods for purification of arylsulfatase a |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015008875A MX2015008875A (es) | 2015-10-22 |
| MX372711B true MX372711B (es) | 2020-04-21 |
Family
ID=50002885
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008875A MX372711B (es) | 2013-01-09 | 2014-01-09 | Metodos para la purificacion de arilsulfatasa a. |
| MX2020003798A MX2020003798A (es) | 2013-01-09 | 2015-07-08 | Metodos para la purificacion de arilsulfatasa a. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003798A MX2020003798A (es) | 2013-01-09 | 2015-07-08 | Metodos para la purificacion de arilsulfatasa a. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11407984B2 (https=) |
| EP (1) | EP2943568B1 (https=) |
| JP (5) | JP6427502B2 (https=) |
| CN (4) | CN104903442A (https=) |
| AU (3) | AU2014205441B2 (https=) |
| BR (1) | BR112015015948B1 (https=) |
| CA (1) | CA2896979C (https=) |
| EA (1) | EA030551B1 (https=) |
| ES (1) | ES2768261T3 (https=) |
| HK (1) | HK1214622A1 (https=) |
| MX (2) | MX372711B (https=) |
| WO (1) | WO2014110246A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2625511T3 (es) * | 2011-07-08 | 2017-07-19 | Shire Human Genetic Therapies, Inc. | Métodos para la purificación de arylsulfatasa A |
| AU2014205441B2 (en) | 2013-01-09 | 2019-12-12 | Takeda Pharmaceutical Company Limited | Methods for purification of arylsulfatase A |
| EP3236772A4 (en) * | 2014-12-22 | 2018-10-17 | Alexion Pharmaceuticals, Inc. | Methods of purifying recombinant proteins |
| EP3337819B1 (en) * | 2015-08-20 | 2024-02-21 | F. Hoffmann-La Roche AG | Method of purifying for producing recombinant polypeptides using fkpa |
| CA3015685A1 (en) * | 2016-03-16 | 2017-09-21 | Phoenix Tissue Repair, Inc. | Methods of purifying collagen 7 |
| US11584777B2 (en) | 2017-08-31 | 2023-02-21 | Green Cross Corporation | Method for purifying a sulfatase protein |
| WO2019126376A1 (en) * | 2017-12-19 | 2019-06-27 | Shire Human Genetic Therapies, Inc. | Purified arylsulfatase a and compositons thereof |
| KR20250016468A (ko) * | 2018-02-02 | 2025-02-03 | 엔지반트 테라퓨틱스 게엠베하 | 파버병을 치료하는 방법 |
| KR102791798B1 (ko) * | 2018-04-12 | 2025-04-07 | 암젠 인크 | 안정한 단백질 조성물의 제조 방법 |
| CN112082832B (zh) * | 2019-06-12 | 2022-03-29 | 华南理工大学 | 一种保存城市污水中硫酸酯结合体和葡萄糖苷醛酸结合体的方法 |
| KR102286892B1 (ko) * | 2019-07-08 | 2021-08-06 | 삼천당제약주식회사 | 안과용 단백질 제제의 정제방법 |
| CN110632052A (zh) * | 2019-10-25 | 2019-12-31 | 山西师范大学 | 土壤芳基硫酸酯酶活性的荧光光谱检测法 |
| CN115066266A (zh) * | 2019-12-12 | 2022-09-16 | 伊莱利利公司 | 用环保洗涤剂灭活病毒的方法 |
| CN112759643B (zh) * | 2021-03-17 | 2023-05-30 | 华兰生物工程股份有限公司 | 一种血清白蛋白的脱脂方法 |
| CN116693659B (zh) * | 2023-07-11 | 2025-03-28 | 浙江大学 | 一种分离重组人血白蛋白的两步混合模式层析方法 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314997A (en) | 1980-10-06 | 1982-02-09 | Edward Shanbrom | Purification of plasma protein products |
| US4315919A (en) | 1980-10-06 | 1982-02-16 | Edward Shanbrom | Depyrogenation process |
| US4764369A (en) | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
| CA2041280A1 (en) * | 1990-05-10 | 1991-11-11 | Yosuke Sawada | Arylsulfatase |
| NO960163D0 (no) | 1996-01-15 | 1996-01-15 | Thomas Berg | Mutasjonsdeteksjon av bovin |
| AU750143B2 (en) | 1998-01-27 | 2002-07-11 | Zymenex A/S | Method for treating acute intermittent porphyria (AIP) and other porphyric diseases |
| DK2270044T3 (en) | 1998-06-09 | 2015-01-26 | Csl Behring Ag | Liquid immunoglobulin G (IgG) product |
| NZ509135A (en) | 1998-06-09 | 2002-10-25 | Statens Seruminstitut | A third generation intravenous immunoglobulin G (IVIG) purified using column chromatographic ion exchange methods |
| AUPQ026799A0 (en) | 1999-05-10 | 1999-06-03 | Csl Limited | Method of increasing protein stability by removing immunoglobulin aggregates |
| WO2001007065A2 (en) | 1999-07-27 | 2001-02-01 | Hemebiotech A/S | PRODUCTION OF rhPBGD AND NEW THERAPEUTIC METHODS FOR TREATING PATIENTS WITH ACUTE INTERMITTENT PORPHYRIA (AIP) AND OTHER PORPHYRIC DISEASES |
| US6812339B1 (en) | 2000-09-08 | 2004-11-02 | Applera Corporation | Polymorphisms in known genes associated with human disease, methods of detection and uses thereof |
| CA2429210A1 (en) | 2000-11-15 | 2002-05-23 | Jason C. Goodrick | Expression system for recombinant proteins |
| AU2002317700A1 (en) * | 2001-06-07 | 2002-12-16 | Hemebiotech A/S | Production of recombinant human arylsulfatase a |
| AU2002317701A1 (en) | 2001-06-07 | 2002-12-16 | Hemebiotech A/S | Production of recombinant human lysosomal alpha-mannosidase |
| EP1402014A1 (en) | 2001-06-29 | 2004-03-31 | Hemebiotech A/S | A process for purification of recombinant porphobilinogen deaminase |
| US7232670B2 (en) | 2001-09-28 | 2007-06-19 | St. Jude Children's Research Hospital | Targeting proteins to cells expressing mannose receptors via expression in insect cells |
| AU2003222568B2 (en) | 2002-01-11 | 2009-05-07 | Bioasis Technologies, Inc. | Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
| WO2003066669A2 (en) | 2002-02-04 | 2003-08-14 | Millipore Corporation | Process for removing protein aggregates and virus from a protein solution |
| US8536315B2 (en) * | 2004-01-30 | 2013-09-17 | Shire Pharmaceuticals Ireland Limited | Production and purification of recombinant arylsulftase |
| SI1740204T1 (en) | 2004-04-01 | 2018-07-31 | Chiesi Farmaceutici S.P.A. | MEDICAL APPLICATION OF ALFA-MANOSIDES |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| ES2928096T3 (es) | 2006-04-04 | 2022-11-15 | Takeda Pharmaceuticals Co | Un proceso para la concentración de un polipéptido |
| BRPI0919879A2 (pt) * | 2008-10-29 | 2016-02-16 | Wyeth Llc | métodos para purificação de moléculas de ligação a antígeno de domínio único |
| US8945895B2 (en) * | 2009-07-31 | 2015-02-03 | Baxter International Inc. | Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof |
| NZ605873A (en) | 2010-06-25 | 2015-02-27 | Shire Human Genetic Therapies | Methods and compositions for cns delivery of arylsulfatase a |
| SMT201600385T1 (it) | 2010-06-25 | 2017-03-08 | Shire Human Genetic Therapies | Trasporto di agenti terapeutici all’snc |
| GB201012603D0 (en) * | 2010-07-27 | 2010-09-08 | Ucb Pharma Sa | Protein purification |
| AU2014205441B2 (en) | 2013-01-09 | 2019-12-12 | Takeda Pharmaceutical Company Limited | Methods for purification of arylsulfatase A |
-
2014
- 2014-01-09 AU AU2014205441A patent/AU2014205441B2/en active Active
- 2014-01-09 EP EP14701454.2A patent/EP2943568B1/en active Active
- 2014-01-09 HK HK16102496.7A patent/HK1214622A1/zh unknown
- 2014-01-09 CN CN201480003307.5A patent/CN104903442A/zh active Pending
- 2014-01-09 WO PCT/US2014/010856 patent/WO2014110246A1/en not_active Ceased
- 2014-01-09 CN CN202510351647.7A patent/CN119979504A/zh active Pending
- 2014-01-09 CN CN202510851520.1A patent/CN120665836A/zh active Pending
- 2014-01-09 US US14/759,645 patent/US11407984B2/en active Active
- 2014-01-09 MX MX2015008875A patent/MX372711B/es active IP Right Grant
- 2014-01-09 JP JP2015551870A patent/JP6427502B2/ja active Active
- 2014-01-09 CN CN202011058581.6A patent/CN112126634A/zh active Pending
- 2014-01-09 BR BR112015015948-6A patent/BR112015015948B1/pt active IP Right Grant
- 2014-01-09 CA CA2896979A patent/CA2896979C/en active Active
- 2014-01-09 EA EA201590826A patent/EA030551B1/ru not_active IP Right Cessation
- 2014-01-09 ES ES14701454T patent/ES2768261T3/es active Active
-
2015
- 2015-07-08 MX MX2020003798A patent/MX2020003798A/es unknown
-
2018
- 2018-06-28 JP JP2018122837A patent/JP2018171067A/ja not_active Withdrawn
-
2019
- 2019-09-25 JP JP2019174155A patent/JP2020015750A/ja not_active Withdrawn
-
2020
- 2020-02-14 AU AU2020201079A patent/AU2020201079B2/en active Active
-
2021
- 2021-11-10 JP JP2021183082A patent/JP7407161B2/ja active Active
-
2022
- 2022-07-01 US US17/810,396 patent/US11884945B2/en active Active
- 2022-08-25 AU AU2022221475A patent/AU2022221475B2/en active Active
-
2023
- 2023-10-04 JP JP2023173170A patent/JP7663649B2/ja active Active
- 2023-12-22 US US18/394,404 patent/US12319940B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX372711B (es) | Metodos para la purificacion de arilsulfatasa a. | |
| PH12020500027A1 (en) | Purification of iduronate-2-sulfatase | |
| CY1124921T1 (el) | Μεθοδοι για την εκχυλιση και τον καθαρισμο μη μετουσιωμενων πρωτεϊνων | |
| MX2025003310A (es) | Integracion dirigida de acidos nucleicos | |
| BR112015019879A2 (pt) | Composições de espécies de variantes moduladas de lisina e métodos para produção e uso das mesmas | |
| BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
| BR112015004467A2 (pt) | método para controlar a heterogeneidade de proteínas | |
| BR112016016916A2 (pt) | método de tratamento de angiodema hereditário (hae) | |
| BR112015013525A2 (pt) | método para produção de uma proteína de fusão, bem como composição compreendendo uma proteína de fusão | |
| EA201391157A1 (ru) | Антагонисты pcsk9 | |
| EA201492185A1 (ru) | Способ получения рекомбинантной идуронат-2-сульфатазы | |
| WO2016022377A3 (en) | Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen | |
| MX391716B (es) | Promotor de catalasa modificado bidireccional de bacilo. | |
| MX378585B (es) | Sistema de expresion bacterial bicistronico | |
| EA202091349A1 (ru) | Способы культивирования клеток | |
| EA201890710A1 (ru) | Способ очистки гидролизата биомассы | |
| EA201990593A1 (ru) | Непрерывный способ для снижения гетерогенности терапевтического белка | |
| CL2019003248A1 (es) | Disminución de homocisteína mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria. | |
| MX383505B (es) | Eliminación de la cistina mediada por enzimas humanas. | |
| EA201000945A1 (ru) | Конструирование системы секреции на основе sm-белков | |
| UY34915A (es) | Purificación de inhibidor de proteasa alfa1 derivado de cultivo celular | |
| EA201790362A1 (ru) | Солюбилизированный фермент и его применения | |
| MX2021016092A (es) | Metodos de purificacion de proteinas. | |
| MX394035B (es) | Procedimiento para preparar una proteina de fusion tnfr-fc que contiene un contenido objetivo de impurezas. | |
| MX2022002774A (es) | Método de captura y purificación de productos biológicos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED |